Passionate Life Sciences Leader | Fast-Tracking Treatments for Patients | Making a Positive Difference ❤️ | HBA Ambassador Champion | WEN (Women Empowerment Network) India Co-Lead
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/grsPew4S
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gGFFDQaj
Clinical Operations Professionals Clinical Research Professionals Business drive to succeed for APAC countries
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gECYqNQY
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/eg3XEfCq
Strategic Transformation | 19 Patents | PSPO™ | PSM™ | LSSWB | LSSYB | LPLG | Microsoft Power BI Certified | Program And Project Management | Vendor Management | Operational Excellence| Data Analytics
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/dczMqHxG
Business Development Director at Fortrea (formerly Covance, Labcorp). Supporting clinical development Phase I-IV for biotech companies
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/gTg2T2rj
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/d95Rs78p
Strategic Transformation | 19 Patents | PSPO™ | PSM™ | LSSWB | LSSYB | LPLG | Microsoft Power BI Certified | Program And Project Management | Vendor Management | Operational Excellence| Data Analytics
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/dczMqHxG
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/e84Zj_7E
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/e5fPTiC3
From patient screening, through cell product infusion and long-term follow-up, the patient journey has many risks that can derail clinical progress. We take a look at six risk nodes, as well as actionable measures designed to mitigate each of these risks. https://lnkd.in/dfmFNwSD
